Journal article

Tumour cell surface antigen targeted therapies in B-cell lymphomas: Beyond rituximab

Matthew Ku, Geoff Chong, Eliza A Hawkes

BLOOD REVIEWS | CHURCHILL LIVINGSTONE | Published : 2017

Abstract

Recent proliferation of novel targeted therapies in lymphoma has been substantial. B-cell receptor pathway inhibitors and immune checkpoint inhibitors have been a major focus, however significant advances in monoclonal antibodies (MoAbs) which directly target malignant cells have also occurred. These MoAbs continue to make significant impact in lymphoma management. Novel dosing schedules of anti-CD20 MoAb rituximab potentially optimise efficacy in specific lymphoma subgroups, as certain populations may be receiving suboptimal doses using current schedules. Next-generation anti-CD20 MoAbs may surpass rituximab in terms of efficacy. MoAbs targeting other B-cell surface antigens and antibody-dr..

View full abstract

University of Melbourne Researchers